Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

[1] Bosch FX(2004)Primary liver cancer: worldwide incidence and trends Gastroenterology 127 S5-S16

[2] Ribes J(2007)Hepatocellular Carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557-2576

[3] Díaz M(2003)Hepatocellular carcinoma Lancet 362 1907-1917

[4] Cléries R(2005)A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst 97 1532-1538

[5] El–Serag HB(2007)Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J Clin Oncol 25 3069-3075

[6] Rudolph KL(2009)A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma Cancer Chemother Pharmacol 63 929-935

[7] Llovet JM(2009)Targeted therapy for hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 6 423-432

[8] Burroughs A(2006)Role of Raf kinase in cancer. therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway Semin Oncol 33 392-406

[9] Bruix J(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390

[10] Yeo W(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34

[1] Bosch FX(2004)Primary liver cancer: worldwide incidence and trends Gastroenterology 127 S5-S16

[2] Ribes J(2007)Hepatocellular Carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557-2576

[3] Díaz M(2003)Hepatocellular carcinoma Lancet 362 1907-1917

[4] Cléries R(2005)A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma J Natl Cancer Inst 97 1532-1538

[5] El–Serag HB(2007)Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin J Clin Oncol 25 3069-3075

[6] Rudolph KL(2009)A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma Cancer Chemother Pharmacol 63 929-935

[7] Llovet JM(2009)Targeted therapy for hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 6 423-432

[8] Burroughs A(2006)Role of Raf kinase in cancer. therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway Semin Oncol 33 392-406

[9] Bruix J(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390

[10] Yeo W(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34